LL-37 + BPC-157
One half calms the immune system. The other is built to provoke it.
The pairing is sold for gut problems: clear the bacteria with one compound, repair the lining with the other. LL-37 works by switching the immune system on, and the research ties that same activity to autoimmune disease. Several guides selling it list active bowel disease as a reason not to take it.
Clear it, then rebuild it.
The logic is sequential and it sounds right. LL-37 is the body's own antimicrobial, expressed in the gut lining, so it is reached for when bacterial overgrowth or infection is suspected. BPC-157 then repairs the damage left behind.[1]
It is the most common stacking partner LL-37 is given. Vendor pages describe the two as synergistic for gut recovery, and the pairing comes up around leaky gut, bowel disease and chronic bloating.[1]
The problem is not the sequencing. It is that the two compounds do opposite things to the immune system, and the research on that is clearer than the research on either compound working.
Four benefits, and how well each one holds up.
The third row is the one worth reading twice. The most common reason for buying this stack appears on the contraindication list of the compound that defines it.
Three questions, answered before anything else.
LL-37 turns your own DNA into an alarm.
LL-37 is the only cathelicidin humans make, produced by skin cells, neutrophils and the lining of the gut. Its job is defence: it punctures bacterial membranes and calls immune cells to the site.[2]
It does something else that is better documented than any benefit claimed for it. LL-37 binds loose DNA and condenses it, and those complexes trigger a receptor called TLR9 that normally ignores the body's own genetic material.[3]
The published description is that LL-37 converts inert self-DNA into a trigger of interferon production, breaking innate tolerance to self-DNA.[3] That is the proposed first step in psoriasis.
It goes further than a mechanism. LL-37 has been reported to act directly as an autoantigen, activating T cells against the body in psoriasis, and antibodies to LL-37 are raised in psoriatic arthritis alongside inflammatory markers.[4] One guide calls it a validated psoriasis autoantigen.[5]
None of that makes LL-37 harmful in a healthy person. It means the compound's defining activity is the same activity implicated in autoimmune disease, and that the line between the two is dose, context and who is taking it.
In bowel disease, the levels track with the damage.
A study measured circulating cathelicidin in two cohorts of patients. Levels correlated with mucosal disease activity in ulcerative colitis, and measuring it alongside C-reactive protein was more accurate than either alone.[6]
That is a marker finding rather than a treatment finding, and it points the opposite way from the sales pitch. In the condition people most often buy LL-37 for, more of it in the blood went with more active disease.
The same paper complicates it. Low cathelicidin was associated with risk of intestinal stricture in Crohn's disease, and low levels elsewhere associate with sepsis and with mortality in severe kidney disease.[6] High levels show up in psoriasis and vasculitis.
So cathelicidin behaves like a quantity the body regulates in both directions rather than something to be topped up. Nothing in that literature measured what happens when it is injected.
The sellers list the buyers.
The contraindication lists on pages selling LL-37 are unusually specific, and unusually long. Across several of them, the conditions named include active psoriasis, rosacea, lupus, rheumatoid arthritis and an active inflammatory bowel disease flare.[5][7]
One describes the autoimmune contraindication as the most important safety consideration with the compound. Another writes that these are not theoretical risks but established findings in peer-reviewed literature.[5]
Bowel disease sits on that list and is also one of the main reasons people buy it. A compound sold for gut inflammation, excluded in gut inflammation, is a contradiction the pages do not resolve.
One page selling LL-37 goes further and names the alternative: for people with autoimmune conditions it suggests BPC-157 or TB-500 instead, as more anti-inflammatory and less immunostimulatory.[1] That is the other half of this stack, recommended on its own.
Reported side effects include burning and swelling at the injection site, plus low-grade fever, fatigue or body aches in the first few days. The same source attributes those to the cytokine release the compound is designed to cause.[1]
Two vials, and the antimicrobial half is the expensive one.
Nobody sells this pair premixed, so it is two purchases.[8] LL-37 has the fewest listings of the two by a wide margin and the higher floor.
Its price spread is also wide, running to more than three times the cheapest listing. BPC-157 is the most widely listed compound in our data, which keeps its floor low.
If the goal is the gut lining rather than the bacteria, BPC-157 with KPV covers repair and inflammation without the immune activation. KPV also has real colitis data in mice. A three-compound version exists too.
No approval, limited human data, and a screening question.
Neither compound is approved anywhere. BPC-157 sits in Category 2 on the FDA's 503A bulk substance list, meaning compounding pharmacies may not use it. Everything sold online is research chemical material.
Human safety data for LL-37 given as a treatment are described as limited. One clinical source takes what it calls a conservative posture, screening for autoimmune and inflammatory skin disease before prescribing.[7]
That screening question is the useful part of this page. A history of psoriasis, rosacea, lupus or inflammatory bowel disease changes the risk calculation, and it is not something a vendor page can assess.
Anyone with gut symptoms serious enough to be considering this has a reason to get a diagnosis first. Bacterial overgrowth, inflammatory bowel disease and coeliac disease produce overlapping symptoms and have different treatments, and two of them have treatments that work.
What people ask about this stack
Is LL-37 safe to take with BPC-157?
No trial has tested the pairing. The specific concern is not an interaction but a direction: BPC-157 is described as anti-inflammatory, and LL-37 works by stimulating immune activity. Guides selling LL-37 list active autoimmune conditions and an inflammatory bowel disease flare among reasons not to use it, and one suggests BPC-157 on its own instead for people in that group.
Why is LL-37 linked to autoimmune disease?
LL-37 condenses loose DNA into complexes that set off TLR9, a receptor which normally ignores the body's own genetic material. Published work describes this as converting inert self-DNA into a trigger of interferon production and breaking innate tolerance to it, the proposed first step in psoriasis. LL-37 has also been reported to act directly as an autoantigen, activating T cells against the body.
Does LL-37 help inflammatory bowel disease?
No trial supports it, and the available evidence points the other way. A study in two patient cohorts found circulating cathelicidin correlated with mucosal disease activity in ulcerative colitis, meaning more of it went with more active disease. The same paper found low levels associated with stricture risk in Crohn's disease, so the relationship runs in both directions. Nothing in that work measured injected LL-37.
Who should avoid LL-37?
Guides selling it name active psoriasis, rosacea, lupus, rheumatoid arthritis and an active inflammatory bowel disease flare, along with pregnancy and ongoing cancer treatment. One calls the autoimmune exclusion the single most important safety consideration for the compound. A clinical source screens for autoimmune and inflammatory skin disease before prescribing and monitors during a course.
What are the side effects?
Reported effects include burning, redness or swelling at the injection site, and low-grade fever, fatigue or body aches in the first few days. One source attributes those systemic symptoms to the cytokine release and immune cell recruitment the compound is designed to produce. That makes them a sign it is working rather than a sign it is contaminated.
Is there a gentler option for the gut?
BPC-157 with KPV covers repair and inflammation without the immune activation, and KPV has genuine mouse colitis data behind it. A three-compound version adds glutathione on much weaker grounds. Anyone with symptoms serious enough to consider injecting something has a reason to get a diagnosis first. Bacterial overgrowth, inflammatory bowel disease and coeliac disease overlap in symptoms and differ in treatment. Compare against the other stacks.
What this page is built on
- 01LL-37 compound guide. Source for LL-37 being the only cathelicidin expressed in humans, for its expression in the gastrointestinal tract and use for leaky gut, bowel disease and chronic bloating, for it being commonly stacked with BPC-157 for gut recovery, for injection site burning, redness and swelling, for low-grade fever, fatigue and body aches attributed to cytokine release, and for the suggestion that people with autoimmune conditions consider BPC-157 or TB-500 instead as more anti-inflammatory and less immunostimulatory.
- 02Cathelicidin background. LL-37 is an antimicrobial peptide synthesised by epithelial cells, neutrophils and lymphocytes, acting as a defence mechanism against bacterial, viral and fungal infection. Also the source for its role in re-epithelialisation of human skin wounds.
- 03Complexation of the human cathelicidin LL-37 with nucleic acids. Biophysical Journal. Full text. Source for LL-37 converting inert self-DNA into a trigger of interferon production through condensation of DNA, with the resulting complexes triggering TLR9 to break innate tolerance to self-DNA and drive autoimmunity in psoriasis, and for LL-37 and nucleic acid complexes being a suggested contributing factor in psoriasis and systemic lupus erythematosus.
- 04The role and potential application of antimicrobial peptides in autoimmune diseases. PMC7225298. Source for LL-37 being positively associated with the pathogenesis of psoriasis, rheumatoid arthritis and systemic lupus erythematosus, for LL-37 and autoantibodies to it being elevated in psoriatic arthritis and correlating with clinical inflammatory markers, and for LL-37 directly triggering T cell activation as an autoantigen in psoriasis.
- 05LL-37 research guide. Source for LL-37 being described as a validated psoriasis autoantigen via TLR9-mediated dendritic cell activation, for the statement that these are established findings in peer-reviewed literature rather than theoretical risks, for rosacea and abnormal cathelicidin processing, and for the populations of greatest concern including active or previous psoriasis, rosacea-prone skin and active malignancy.
- 06Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease. PMC5427565. Two cohorts, levels measured by ELISA. Co-evaluation of LL-37 with C-reactive protein was more accurate than either alone. Also the source for low cathelicidin associating with sepsis and with mortality in severe renal disease, and high levels with psoriasis and vasculitis.
- 07Clinical guidance on LL-37. Source for human safety data for therapeutic LL-37 being limited, for a conservative prescribing posture that screens for autoimmune and inflammatory skin disease history and monitors during a course, for the dual immunomodulatory description, and for active autoimmune or inflammatory skin disease and pregnancy being listed as reasons not to use it.
- 08Peptide Decoding vendor pricing data. Lowest in-stock single-compound listings for LL-37, BPC-157 and KPV, with listing counts, computed at page load. No premixed listing combining LL-37 with any other compound.